A study in healthy people to compare two different Sifrol® tablets
This research study is comparing two different versions of a medication known as Sifrol®. Doctors want to understand if these two versions are absorbed and used by the body in the same way. This type of study is called a 'bioequivalence' study and is a very early step in checking new medicines. It helps ensure that different forms of a drug can be used interchangeably and will have the same effect. We are looking for healthy adults, aged 18 or older, both men and women, to take part. Your health and safety are our top priority throughout the study.
At a glance
What is this study about?
This research study, called "A study in healthy people to compare two different Sifrol® tablets," is looking into a medication called Sifrol. You might know it is used to treat conditions like Parkinson's disease or restless legs syndrome. However, this study isn't about treating those conditions. Instead, it's about comparing two different ways the Sifrol medicine is made (two different tablets). The main goal is to see if your body processes both of these tablets in the exact same way. This includes how much of the medicine gets into your bloodstream and how quickly.
This kind of study is known as a "bioequivalence" study. Imagine you have a branded carton of milk and a supermarket-own brand carton – both say they're full-fat milk. A bioequivalence study is a bit like checking if your body gets the same goodness from both. In medicine, it's really important because it helps doctors and pharmacists understand if different versions of a drug will work identically. If they do, it means patients can safely switch between them.
This study is in an early stage, which we call "Phase I" or "Human Pharmacology." This means it's one of the first times a new form of a medicine is given to people, specifically healthy volunteers. We carefully watch how the medicine acts in the body, which helps ensure future patients can receive safe and effective treatment, no matter which version of the tablet they are prescribed.
Key takeaways
- This study compares two Sifrol® tablets in healthy adults.
- It checks how the body absorbs and uses the medicine.
- Both men and women, aged 18 and over, can take part.
- Your health and safety are the most important focus.
- You have the right to leave the study at any time.
Who may be eligible?
To be able to take part in this study, you generally need to be a healthy adult who is at least 18 years old. There's no upper age limit, meaning people over 18, like those in their 20s, 30s, 40s, and older, are welcome to consider joining. Both men and women can participate in this research.
Being 'healthy' means that you don't have any significant ongoing medical conditions that could affect how your body handles the study medication or might put you at extra risk. This would typically be checked through a medical examination and some tests before joining.
There might be other specific health requirements or conditions that would mean you couldn't join the study, even if you feel well. These are put in place to keep you safe and ensure the study results are clear. A doctor involved in the study would discuss all the exact requirements with you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you consider yourself generally healthy?
- Are you able to attend several clinic visits, possibly including overnight stays?
- Are you willing to have blood tests?
- Are you able to follow specific instructions from the study team?
- Are you a man or a woman? (Both can apply)
What does participation involve?
If you decide to take part, you would be invited for an initial screening visit. This involves a health check-up, including blood tests and possibly other examinations, to make sure you are healthy and meet all the study's requirements. If you're eligible, you would receive doses of the Sifrol® tablets, one type at a time, with a break in between. The study would involve several visits to the study clinic, likely including an overnight stay or two for each dosing period, where doctors and nurses can closely monitor you and take blood samples at specific times. You might need to follow certain dietary rules or avoid specific activities around the dosing times. After the last dose and clinic visits, there would usually be a final follow-up health check, either in person or by phone. The total time you would be involved in the study, from your first visit to your final check-up, will be clearly explained to you.
Potential risks and benefits
Locations (1)
- —UnverifiedGermany
Common questions
What is Sifrol® used for generally?
Sifrol® is a medicine used to treat conditions like Parkinson's disease and restless legs syndrome. However, in this study, we're not treating any illness, just looking at how healthy people's bodies handle the medicine.
Why are you comparing two different tablets?
We want to check if two different versions of the Sifrol® tablet are absorbed and used by the body in the same way. This helps make sure all versions of the medicine work identically for patients.
Will I feel unwell during the study?
The study team will carefully monitor you for any side effects, and your safety is the top priority. All known possible side effects will be discussed with you before you agree to take part.
Do I have to do anything special before or during the study?
You might need to follow specific instructions, like avoiding certain foods or activities, for a short time around when you take the medicine. All instructions will be given to you clearly.
Will I get paid for taking part?
Some studies offer payment for your time and expenses. This will be fully explained to you by the study team if it applies to this particular study.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.